Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

Documenti analoghi

• Paroxysmal Nocturnal Haemoglobinuria‐Associated Acute Cutaneous Thrombosis and Haemolysis in the Setting of Parvovirus B19 and Varicella Zoster Virus Infection
  di: Louise J. Potter, et al.
  Pubblicazione: (2026)
• Comparative Efficacy of Complement Inhibitors in Complement Inhibitor–Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta‐Analysis of Randomized Trials
  di: Rehan Ishaque, et al.
  Pubblicazione: (2026)
• Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland
  di: Anders Rønneholt‐Frederiksen, et al.
  Pubblicazione: (2025)
• Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors
  di: Shreyans Gandhi, et al.
  Pubblicazione: (2026)
• EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non‐Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial
  di: Jun Ho Jang, et al.
  Pubblicazione: (2025)